2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Cell Expansion, Emerging Technologies, Gene Editing, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Transplantation, Gene Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Immunodeficiency, Myeloid Malignancies, Acute Myeloid Malignancies, Research, AML, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

6064 AAV8-FVIII gene therapy (GS1191-0445) in Chinese subjects with severe hemophilia A: Integrated pilot phase I, phase I/II, and phase III trials

Dai Xinyue, Huafang Wang2, Hu Zhou, MD3, Yu Yan, MD4, Yaming Xi5, ZePing Zhou, MD6, Changcheng Zheng7, Yun Chen8, Chenghao Jin9, Xielan Zhao10, Tienan Zhu, MD, PhD11, Rongfu Zhou12, Jing Sun13, Tenghui Yu14, Jiaoyang Chen15, Hongyuan Wang16, Mankai Ju17, Sun Ting, PhD18, Yanmei Xu19, Renchi Yang20, Yu Hu21, Lei Zhang, MD22
1 1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China., Tianjin, China
2 Institute of Hematology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
4 North China University of Science and Technology Affiliated Hospital, Tangshan, China
5 The First Hospital of Lanzhou University, Lanzhou, China
6 Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China
7 Anhui Provincial Hospital, Hefei, China
8 Central Hospital Affiliated to Shandong First Medical University, Jinan, China
9 Jiangxi Provincial People's Hospital, Nanchang, China
10 Xiangya Hospital of Central South University, Changsha, China
11 Peking Union Medical College Hospital, Beijing, China
12 Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China
13 Nanfang Hospital Southern Medical University, Guangzhou, China
14 Gritgen Therapeutics Co., Ltd, Suzhou, China
15 Gritgen Therapeutics Co., Ltd, Suzhou, China
16 Gritgen Therapeutics Co., Ltd, Suzhou, China
17 1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China., Tianjin, China
18 1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China., Tianjin, China
19 1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China., Tianjin, China
20 1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China., Tianjin, China
21 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
22 1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China., Tianjin, China

Introduction:

Hemophilia A is an X-linked bleeding disorder caused by pathogenic variants in the Factor VIII (VIII) gene, resulting in deficient coagulation FVIII. GS1191-0445 is an investigational liver-targeted gene therapy vector based on adeno-associated virus serotype 8 (AAV8). It utilizes a liver-specific promoter to drive expression of a human FVIII (hFVIII) transgene. We present integrated data from three clinical studies in Chinese patients with severe hemophilia A to evaluate the efficacy, durability, and safety of a single intravenous infusion of AAV8-hFVIII and to determine whether FVIII expression is maintained at levels sufficient for bleeding prophylaxis.

Methods:

A total of 76 subjects with severe hemophilia A received a single intravenous infusion of GS1191-0445 across a pilot Phase I study (NCT04728841), a Phase I/II trial (NCT07548411), and an ongoing Phase III trial (NCT06833983).

There were three dose cohorts. In the first pilot Phase I study, 12 subjects with Hemophilia A were enrolled and assigned to one of two dose cohorts: a low-dose group (6 subjects, 2×10¹²vg/kg) and a high-dose group (6 subjects, 4×10¹²vg/kg). In the phase ?/? trial, 7 subjects were enrolled and infused with an intermediate dose of 3×1012vg/kg. A Phase III trial were initiated and 57 subjects received the same dose as Phase I trial.

Two immunosuppressive regimens were applied, prophylactic prednisone alone or prednisone combined withtacrolimus, were selected to mitigate the potential AAV capsid immune response, starting 7-days prior to study drug infusion and continuing for at least 12 weeks post-infusion.

Primary endpoint was annualized bleeding rate (ABR), and secondary endpoints included FVIII activity (one-stage assay), and adverse events.

Results:

F? activity peaked at 6-8 weeks post-infusion of GS1191-0445. In the low-dose cohort (2×10¹² vg/kg, n=6), a 208-week median follow-up has achieved (range 156-260 weeks). Mean (median) F? activity at week 208 among low-dose cohort was 13.8% (7.4%) (one-stage assay; range 0.1-49.5%). In the high-dose cohort (4×10¹² vg/kg, n=6), median follow-up was 169 weeks (range 156-195 weeks), with sustained high-level F? activity [mean (median) 50.4% (48.7%), range 31.5-78.2%]. ABR in the high-dose cohort decreased by 98.7%, declined from 13.00 bleeds per/year (range 8.0-20.0) before treatment to 0.17 bleeds per/year (range 0-1) during weeks 3-52.

In the phase ?/? trial, an intermediate dose of 3×1012vg/kg was administered to seven subjects. Following a median follow-up of 130 weeks (all 7 subjects followed-up of 130 weeks), mean (median) FVIII activity was 43.2% (31.8%) (range 1-115.8%). Concurrently, the ABR declined by 99.40% from 25.40 bleeds per/year at baseline to 0.15 bleeds per year over 3-52 weeks post-infusion.

Among 19 subjects in pilot Phase I and Phase I/II study, all experienced ≥1 treatment-emergent adverse event (TEAE),most were Grade 1-2, with transaminase elevation (ALT/AST) most common (12/19, 63.2%), manageable with immunosuppression. No Grade ≥3 TEAEs occurred. Serious adverse events (SAEs) were reported in 5 participants (1 in the 2×1012 cohort, 2 in the 4×1012 cohort, and 2 in the 3×1012 cohort). No thrombotic events, no FVIII inhibitors, and no discontinuations due to safety were observed.

In the ongoing Phase III study, a median follow-up was 36 weeks (range 22-52 weeks). At Week 36, mean (median) FVIII activity was 103.1% (88.2%) (range 16.98-248.6%).

Conclusion:

Single-infusion AAV8-hFVIII gene therapy with GS1191-0445 demonstrated durable FVIII expression and marked ABR reduction in Chinese patients with severe hemophilia A. Subjects receiving 3×10¹² vg/kg or 4×10¹² vg/kg achieved a substantial reduction in ABR and enabled discontinuation of exogenous FVIII replacement. Prophylactic glucocorticoid-based immunosuppression, with or without tacrolimus may benefit by suppressing induced immune responses. These data support further evaluation of low-vector-dose AAV gene therapy in severe hemophilia A.

Dai Xinyue: No relevant conflicts of interest to declare.